Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Guangzhou Baiyunshan Pharmaceutical Holdings Company ( (HK:0874) ) is now available.
Guangzhou Baiyunshan Pharmaceutical Holdings has named 37-year-old senior engineer Liu Hong as the employee representative director for its tenth board, following an employee representative meeting held under Chinese company law and the firm’s articles of association. Liu will serve alongside non-employee directors to be elected at the 2025 annual general meeting, with his term aligned to the full tenure of the new board.
Liu brings extensive credentials in pharmaceutical R&D and innovation management, including leadership roles at Baiyunshan research units and Guangzhou Pharmaceutical Holdings, as well as multiple national and provincial awards for scientific and engineering achievement. His appointment strengthens the board’s technical and innovation expertise and is structured so that he receives no extra director fees beyond his existing remuneration within the group, underscoring a governance approach that integrates frontline research leadership into board-level decision-making.
More about Guangzhou Baiyunshan Pharmaceutical Holdings Company
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited is a major Chinese drug maker engaged in pharmaceutical research, development and manufacturing, with a portfolio spanning traditional and modern medicines and health products. Listed in Hong Kong, it operates under the Guangzhou Pharmaceutical Holdings umbrella and focuses on innovation platforms and commercialisation of biomedical technologies in mainland China.
Average Trading Volume: 1,288,691
Technical Sentiment Signal: Sell
Current Market Cap: HK$40.13B
See more insights into 0874 stock on TipRanks’ Stock Analysis page.